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INTRODUCTION 
 
Childhood obesity is one of the most serious public health challenges of 
the 21st century. The problem is global and is steadily increasing in many low 
and middle income countries, particularly in urban settings. The prevalence has 
increased at an alarming rate. Obesity in childhood predisposes to many 
conditions like insulin resistance and diabetes mellitus, coronary artery disease 
and musculoskeletal problems. Childhood obesity has been associated with 
significant morbidity and mortality in adulthood independent of adult weight 
and risk factors. The obesity data of children is shown below in the Table 1.  
YEAR ORGANISATION / 
COUNTRY 
OBESITY ESTIMATION 
2013 International Obesity 
Task Force (IOTF)1 
200 million school children: 
overweight / obese 
2014 WHO children < 5 years : about than 41 
million obese/overweight 
2013 CDC2  Children and adolescents (2-19 
years): prevalence of obesity 17% 
(12.7 million children and 
adolescents for the past 10 years) 
2014-15 National Child 
Measurement 
Programme (NCMP)3  
 
Children between 4-5 years: 
9.5% obese and overweight 
Children between 10-11 years: 
19.1% obese 
1981- 2013 Indian Journal of 
Medical 
Research, India4 
 
52 studies in 16 States included 
combined prevalence of 19.3% 
estimated  
( using pooled data after 2010 ) 
Table 1: Obesity statistics in children 
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Global increases in childhood overweight and obesity are attributable to 
a number of factors including: 
1.  A global shift in the diet towards increased intake of energy-dense foods 
that are high in fat and sugars but low in vitamins, minerals and other 
healthy micronutrients; 
2. A trend towards decreased physical activity levels due to the increasing 
sedentary nature, changing lifestyles, increasing hour of  inactivity due 
to television, video games and computer which has replaced many 
outdoor activities, changing modes of transportation, and increasing 
urbanization. 
DEFINITION: 
The World Health Organization (WHO) defines obesity as “abnormal or 
excessive accumulation of fat in adipose tissue to the extent that health may be 
impaired”  
Body mass index-BMI (calculated as weight in kilograms divided by 
height in meters squared) is the preferred method for the recognising the 
overweight or obese children5.  
Other methods to measure obesity include skin- fold thickness, 
densitometry, computed tomography or magnetic resonance imaging and 
electrical impedance.  
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CLASSIFICATION OF BMI: 
Obesity is recognised in children using the age and gender specific 
charts for BMI released by the Centre for Disease Control (CDC)6. 
Between 5th percentile to 84th 
percentile 
Normal  
Between the 85th-95th percentile Overweight 
BMI greater than the 95th percentile Obesity 
 
Table 2: BMI cut offs as per CDC 
According to WHO7, Overweight is defined as > +1 Standard deviation 
(equivalent to BMI 25 kg/m2 at 19 years), while obesity is defined as > +2 
Standard deviation (equivalent to BMI 30 kg/m2 at 19 years)  
Indian Academy of Paediatrics (IAP)8 has classified children aged 5-18 
years based on their BMI as below 
Between 23 to 27 adult equivalent 
centiles 
Overweight  
>27 adult equivalent centiles Obesity  
 
Table 3: Definition of overweight and obesity as per IAP 
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PATHOGENESIS: 
Regulation of body weight is based on energy intake and energy 
expenditure, known as energy balance equation. 
                     
Figure 1: Energy balance equation 
Imbalance between energy intake and energy expenditure will have 
direct consequence on the body weight. Genetic, environmental, endocrine, 
neuronal and behavioural factors by exerting their influence on energy balance 
equation can lead to obesity. 
                      
Figure 2: Factors affecting obesity 
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Endocrine and neuronal factors: 
Set point mechanism based on a sensing system in adipocyte and 
adipostat receptor in hypothalamus, is a physiological phenomenon in which 
when fat stores are depleted adipocytes sends signal to adipostat receptor in 
hypothalamus which responds by stimulating hunger and decreasing energy 
expenditure and vice versa.  
 Satiety Appetite 
Gastrointestinal 
hormones 
Cholecystokinin, 
glucagon like peptide 1, 
peptide YY 
Ghrelin 
Adipose tissue Leptin  
Neuropeptides  Pro opio 
melanocortin(POMC), 
cocaine and amphetamine 
related transcript (CART) 
Neuropeptide Y(NPY), 
agouti gene related 
peptide( AgRP) and 
orexin 
 
Table 4: Endocrine and Neuronal factors regulating obesity 
Leptin is directly involved in satiety with low levels of leptin related to 
obesity. Adiponectin levels which are reduced in obesity is associated with 
insulin resistance. 
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Role of Genes: 
 
 
 
 
 
 
 
 
 
  
                             Figure 3: Genes involved in obesity 
Mutations in genes encoding adipose-tissue-secreted hormones (e.g. 
leptin), neuropeptides (e.g. proopiomelanocortin, cocaine- and amphetamine-
regulated transcript protein(CART) , and melanocortin 4, or defects in the 
receptors for these substrates account for monogenetic forms of obesity as 
depicted in the figure 3 above . 
DECREASE OF MC4 
RECEPTORS INHIBITION 
Alpha - MSH 
ACTIVATION OF MC4 
RECEPTORS 
  DECREASE IN APPETITE 
ADIPOCYTE 
LEPTIN OTHER  EFFECTS 
ACTIVATION OF RECEPTORS 
IN HYPOTHALAMUS 
INCREASE OF  
CART  
EXPRESSION 
INCREASE OF  
POMC  
DECREASE  OF  
AgRP  
EXPRESSION 
DECREASE OF  
NPY  EXPRESSION 
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Role of environment: 
Role of the environmental changes causing obesity is probably the most 
important cause of increasing overweight and obesity epidemic.  
Extreme changes in life style and behaviour throughout the world in the 
past few decades have led to increased sedentary activities with increased hour 
of inactivity due to majority of time spent on watching television, video games, 
cell phones and computers which has replaced most of the outdoor and physical 
activities. Television watching has been directly related with obesity in 
children, with a rate of obesity being about 8.3-times higher in children who 
watch television for more than 5 hours per day compared with children who 
watch up to 2 hours of television per day9.  
Mode of transportation has also been changing with most children using 
elevator rather than stairs, using vehicles for short distance rather than walking. 
Because of urbanisation most families have both parents working and their lack 
of time to supervise the children regarding food habits and physical activities is 
also on the rise.  
Physical activity in schools is also on the declining levels with only 25-
30% children actively engaging in physical activities10. It has been postulated 
that a steady decline in physical activity among all age groups has heavily 
contributed to rising rates of Obesity all around the world11. 
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The 1993 International Consensus Conference on Physical Activity 
Guidelines for Adolescents states that 
1. All adolescents should be physically active daily, or nearly every day, as 
part of play, games, sports, work, transportation, recreation, physical 
education, or planned exercise in the context of family, school, and 
community activities. 
2.  Adolescents should engage in three or more sessions per week of 
activities that last 20 minutes or more at a time and that require 
moderate to vigorous levels of exertion. 
Healthy Food habits have been left behind and fast food items have 
taken an upper hand in most of the urban families. Fast food with high calorie 
content, fat, simple sugar , sodium and low fibre content and micronutrients has 
become a routine in majority of school going children. Effect of nutrients on 
satiation and satiety has been studied recently. Satiation refers to the 
suppression of hunger after the ingestion of a certain amount of food whereas 
satiety describes the period of time of absence of hunger between meals. It is 
important to assess the satiating capacity of the nutrients because the ability of 
the different macronutrients to stimulate satiety and to suppress subsequent 
food intake is not equal. Proteins have the greater satiating capacity; 
carbohydrates, which are also able to decrease the amount of food ingested at 
the next meal, follow them. By contrast, lipids have a less potent satiating 
effect than proteins and carbohydrates Meals with a high lipid content favour 
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passive overconsumption because the high-energy density promotes energy 
intake.  As a result, individuals consuming high-fat foods are more likely to 
gain weight and become obese. Intermittent snacking between meals and 
increased preference for sweetened beverages12 among children which is on a 
rise steadily over the last few decades has been directly linked to overweight 
and obesity. 
Behavioural changes: 
Urbanisation and modernisation has led to increasing stress in both 
children and adults. Most of the people resort to eating as a stress reliever and it 
increases the caloric consumption. 
Due to stress the amount of time spent for sleep is decreased. Chronic 
sleep deprivation leads to decreased leptin levels and increased ghrelin and 
orexin levels which causes increased feeding promoting obesity. 
Other behavioural eating patterns associated with adolescent obesity are 
1) To seek food in the absence of hunger: Eating in the absence of hunger 
(EAH) may be a behavioural trait through which obesity-promoting 
genes promote positive energy balance13. 
2)  Absence of a control over eating 
3)  To seek food in response to sadness, boredom and restlessness. 
4)  To seek food as a reward. 
5)  To sneak or hide food. 
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6)  Binging and use of in appropriate behaviours like purging, fasting or 
excessive exercises. 
7)  To skip or delay breakfast 
8)  Evening hyperphagia 
9)  Night awakenings and binging 
10)  Frequent visits to fast food restaurants 
11)  Eating lunch or dinner in groups 
 
COMORBITIES: 
Obesity related Comorbidities can be broadly classified as depicted in 
the figure below 
                                  
                               Figure 4: Classification of comorbidities 
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Pathogenesis of obesity related comorbidities is depicted in the figure below 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Pathogenesis of comorbidities 
Pathogenesis of comorbidities of obesity is mainly due to tissue hypoxia which 
causes inflammation and release of markers which causes increased endothelial 
vascular permeability and dysfunction. 
 
 
          Overgrowth  
Tissue Hypoxia 
Inflammation   (Secondary to hypoxia and oxidative stress) 
Recruitment and activation of macrophages in the tissue 
Increased vascular endothelial permeability & dysfunction 
Inflammatory markers secreted by the cells and oxygen free radicals 
resulting from oxidative stress 
Increased Interleukin-6, CD8+T4 
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Medical 
Comorbidities 
Bone And Joint 
 
Reproductive 
 
Cardiovascular 
Respiratory 
Gastro Intestinal Tract 
Obstretric And Perinatal  
 
Cutaneous 
Malignancies 
 
Metabolic Syndrome 
 
Miscellaneous 
 
Nervous 
The medical co-morbidities affect most of the systems of our body. The most 
common systems are shown in Figure 6 below: 
 
  
 
 
 
 
 
Figure 6: Obesity related comorbidities 
METABOLIC SYNDROME: 
Metabolic syndrome also known as metabolic syndrome X, syndrome 
X, insulin resistance syndrome, Reaven's syndrome is a combination of medical 
disorders that increase the risk of developing cardiovascular diseases and 
diabetes. Its prevalence in adults is approximately 20% of individual >20 years 
of age and 40% of the population >40 years of age. Prevalence of metabolic 
syndrome is increasing in India14. 
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Metabolic syndrome consists of 
1)  Obesity 
2)  High fasting triglycerides 
3)  Insulin resistance(IR) 
4)  Impaired glucose tolerance 
5)  Hypertension 
6)  Low HDL (high density lipoprotein) 
 WHO Criteria - the World Health Organization bases its definition on 
presence of insulin resistance plus two of the following: 
•  High blood pressure (>=140 mm Hg systolic or >=90 mm Hg diastolic) or 
taking blood pressure medication 
•  Plasma triglycerides >=150 mg/dL (>=1.7 mmol/L) 
•  HDL cholesterol <35 mg/dL (<0.9 mmol/L) in men or <39 mg/dL (1.0 
mmol/L) in women 
•  BMI greater than 30 and/or waist: hip ratio >0.9 in men, >0.85 in 
women 
•  Urinary albumin excretion rate >=20 μg/min or albumin:creatinine ratio 
>=30 mg/g 
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INSULIN RESISTANCE:  
Insulin resistance is defined as an impaired ability of plasma insulin at 
usual concentrations to adequately promote peripheral glucose disposal, 
suppress hepatic glucose output and inhibit very low density lipoprotein 
(VLDL) output. Insulin resistance results in compensatory increase in insulin 
secretion. The resulting hyperinsulinemia overcomes the insulin resistance for 
some time and keeps the blood sugar in normal range. However when relative 
beta cell insufficiency also sets in, overt diabetes develops. 
It is increasingly being recognized that Indians are an ethnic group at 
high risk for insulin resistance. According to a large body of epidemiological 
data from many parts of world, the seeds of insulin resistance are sown during 
prenatal life itself. Low birth weight and more so intra uterine growth 
retardation followed by rapid catch-up growth and relative postnatal obesity 
have been shown to be associated with insulin resistance15,16. 
Genes involved in insulin resistance 
The pathogenesis of insulin resistance is multifactorial. Thus, several 
molecular pathways in energy homeostasis, lipid metabolism, insulin receptor 
signalling pathway, cytokines, hormone-binding proteins including serine 
protease inhibitors (SERPINS), and other protease regulators are responsible 
for the development of insulin resistance, obesity, or lipodystrophy. 
In the energy homeostasis pathway, uncoupling proteins, leptin-
proopiomelanocortin (POMC), ghrelin-neuropeptide Y (NPY), and sympathetic 
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nervous system regulation pathways are important. In the insulin-signalling 
pathway, mutations in insulin receptors, development of insulin receptor auto-
antibodies, and defects in plasma cell membrane glycoprotein-1 and glucose 
transporter 4 (GLUT4) molecules are reported. In the lipid homeostasis 
pathway, adipocyte-derived hormones, leptin, adiponectin, resistin, 
peroxisomal proliferator-activated receptor-γ (PPAR- γ ) and PPAR-α are 
variously involved, as are lipoprotein lipase and genes responsible for adipose 
tissue formation.  
Birth weight and length-insulin resistance: 
An increased incidence of adulthood diseases, such as cardiovascular 
diseases, type 2 diabetes, and hypertension, is noticed in small for gestational 
(SGA) babies. Insulin resistance is particularly apparent when an SGA new 
born undergoes rapid postnatal weight gain. The Early Bird Study suggested 
that insulin resistance at 5years was related not to birth weight, but, rather, to 
weight after catch-up growth, especially in girls15. Such growth patterns 
following foetal growth restraint are associated with maternal-uterine factors 
such as primiparity, smoking, restrictions in the maternal diet, maternal insulin 
resistance, and gestational diabetes (Fig-7). Alternatively, if an inherited insulin 
resistance state was manifested in utero, then diminished foetal growth with 
SGA might be anticipated, because insulin is a powerful prenatal growth 
hormone (Fig-8). Curiously, large for gestational age children are also at risk of 
insulin resistance as well. A U-shaped relation between birth weight and fasting 
insulin, BMI and fat mass has been established17. 
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Figure 7: Thrifty gene hypothesis 
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Figure 8: Foetal Insulin hypothesis 
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ROLE OF MAGNESIUM IN INSULIN RESISTANCE: 
Magnesium is the second most abundant intracellular divalent cation18. 
Magnesium is widely distributed throughout the body, but more concentrated 
in organs like bone, muscle and heart. The concentration of magnesium in 
plasma of normal individuals remains fairly constant throughout because of the 
various factors regulating serum magnesium level. 
Among the various factors which regulate magnesium level, insulin 
deserves a special mention because it is one of the important factor that 
controls magnesium level. On the other hand magnesium also influences 
insulin level and action.  
Role of magnesium on insulin resistance can be explained by the 
physiologic mechanism of magnesium acting as a cofactor for over 300 
enzymes involved in carbohydrate metabolism19. In addition to it magnesium 
acts as a second messenger for insulin action on tyrosine kinase receptor. 
Phosphorylase b kinase activity which releases glucose-1-phosphate from 
glycogen is also affected by magnesium. Glucose translocation into cell is 
affected by magnesium via its effect on glucose transporter protein activity 4 
(GLUT4)20. 
 A poor intracellular magnesium concentration results in a defective 
tyrosine-kinase activity at the insulin receptor level and exaggerated 
intracellular calcium concentration. Both events are responsible for the 
impairment in insulin action and a worsening of insulin resistance21. In addition 
to the above mechanism, low magnesium concentration of erythrocyte by 
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increasing the membrane microviscosity blocks the action of insulin on its 
receptor22. 
Magnesium effect on insulin resistance is also mediated by its effect on 
lipid metabolism. Magnesium is needed for the activity of lipoprotein lipase 
and Lecithin cholesterol acyl transferase (LCAT) which raises HDL cholesterol 
and lowers triglyceride23. Low magnesium leads to decrease in the activity of 
lipoprotein lipase LCAT, thereby causing low HDL with hypertriglyceridemia. 
Clinical features of insulin resistance syndrome: 
The clinical phenotype of insulin resistance includes central obesity; 
characteristic skin involvement (acanthosis nigricans, skin tags, striae, acne, 
hirsutism, and frontal balding); an allergic diathesis, especially as manifested 
by asthma; hypertension; an atherogenic dyslipidaemia increased VLDL with 
raised triglycerides and reduced levels of the protective high density lipoprotein 
(HDL) cholesterol; early atherosclerosis, tall stature and pseudo acromegaly, 
focal segmental glomerulosclerosis, hepatic steatosis, and adrenal and ovarian 
hyperandrogenism. Importantly, insulin resistance is not infrequent in the 
absence of obesity, whereas even considerably obese persons can be insulin 
sensitive. 
        Obese patients represent heterogeneous subgroups of metabolic and 
phenotypical expressions of insulin resistance, whereas individuals with the 
same Body Mass Index (BMI) can have varying degrees of insulin resistancand 
metabolic compensation. However, most individuals with BMI more than 35–
40 are insulin resistant. 
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Clinical features of Insulin Resistance: 
 
Figure 9: Clinical features of insulin resistance syndrome 
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Hyperinsulinism and insulin resistance are not benign, even without 
Diabetes: 
The majority of persons with insulin resistance will not develop type 2 
diabetes. Some Insulin resistant individuals who may escape diabetes, are still 
prone to other complications, such as early atherosclerosis, progression of 
obesity (especially central type), acanthosis nigricans, increased skin tags, 
hypertension, dyslipidaemia, hyper coagulation, polycystic ovarian syndrome, 
fatty liver infiltration, focal segmental glomerulosclerosis, and an increased 
cancer rate as well. Thus insulin resistant syndrome is not benign even when 
diabetes does not develop24. 
Natural history of the clinical insulin resistance syndrome: 
The natural history of insulin resistance syndrome begins in childhood, 
from the interplay of genetic and environmental factors. Although it is 
generally unclear whether a primarily genetically encoded state of insulin 
resistance and/or satiety disorder appears first, insulin resistance results in 
hyperinsulinism and precocious development of atherosclerosis and type 2 
diabetes25. 
In children, obesity and insulin resistance precede the development of 
hyperinsulinism. The hyperinsulinemia can thus be seen as a compensatory 
mechanism for the pre-existing, genetically programmed insulin resistance 
which represents a mechanism for protection against the development of 
impaired glucose tolerance and diabetes. 
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Insulin hyper secretion (especially portal) leads to increased free fatty 
acid synthesis, especially in the liver and adipose tissue. A compensatory 
increase in glucose oxidation and increased malonyl coenzyme A signalling in 
the face of abundant fatty acids directs diversion away from ß-oxidation to 
compensatory increases in long chain fatty acids and triglycerides synthesis in 
the liver. Normally appetite can be suppressed by both leptin and insulin; 
however, diets high in fat stimulate appetite directly. The liver, in turn, 
becomes insensitive to compensatory leptin signalling to increase ß-oxidation, 
which is blocked in insulin resistance state, because of high levels of malonyl 
CoA. Elevated levels of malonyl CoA block fatty acid ßoxidation, leading to 
triglyceride accumulation in muscle and liver, with impaired serine 
phosphorylation of insulin receptor substrate-1, decreased GLUT4 
translocation, and thereby decreased glucose oxidation. In the pancreatic islets, 
these events lead to activation of caspases and increased ceramide levels 
inducing apoptosis of ß-cells. Type 2 diabetes thus results when there is 
insufficient insulin secretion 
to counter pre-existing insulin resistance. 
HYPERINSULINISM AND INSULIN RESISTANCE ASSOCIATED 
PATHOLOGIES: 
Adipose Tissue 
It is widely believed that obesity itself, especially increased visceral fat 
accumulation, can lead to insulin resistance26. Genetically induced insulin 
resistance can be the primary mechanism underling and evoking the 
 23 
 
progression of obesity. In contrast, non-obese lean individuals can develop 
insulin resistance also.  
Visceral fat 
Visceral fat is a potent modulator of insulin action on hepatic glucose 
production27. Central distribution of body fat (waist/hip ratio,>0.90 in females 
and >1.0 in males) is associated with an increased risk of stroke, Coronary 
artery disease, diabetes, and early mortality and is a more sensitive indicator of 
impending morbidity than absolute fat mass. Waist circumference correlates 
with cardiovascular morbidity as well as BMI.  
Leptin levels are higher in subcutaneous fat and show greater 
correlations with subcutaneous adiposity than with visceral adiposity28. 
Visceral fat tissue, through its portal drainage, is an important source of free 
fatty acids that increase hepatic lipogenesis and decrease glucose oxidation. In 
comparison with subcutaneous fat, visceral fat has more glucocorticoid 
receptors and higher local concentrations of glucocorticoids. Omental adipose 
tissue contains significantly more 11ßhydroxysteroid dehydrogenase type 1 
(11ßHSD1) activity than subcutaneous adipose tissue29, promoting increased 
cortisol production from conversion of inactive cortisone. Growth Hormone 
and Insulin like growth factor-1(IGF-I) was suggested recently to inhibit 
11ßHSD1, whereas in obesity, GH levels are decreased, leading to higher 
11ßHSD1 activity 30. 11ßHSD1 activity correlates with insulin resistance31. 
  A local increase in glucocorticoid hormone action in visceral fat may 
contribute to the pathogenesis of key features of the metabolic syndrome. 
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Increased abdominal striae and biochemically increased urinary free cortisol 
levels in obesity are observed. 
Patients with Cushing’s syndrome have high levels of serum cortisol, 
and the patient with insulin resistance syndrome has low to normal levels, 
though both have increased levels of urinary free cortisol. The explanation lies 
in the decreased levels of corticosteroid-binding globulin (CBG) found in 
insulin resistance syndrome, where circulating cortisol is disproportionately 
free and bioactive, with increased conversion of cortisone to the metabolically 
active cortisol. The clinical distinction between patients with Cushing’s and 
IRS is that the former is invariably growth retarded, in contrast to the child 
with insulin resistance syndrome in whom linear growth is excessive. 
Fatty liver or hepatic steatosis:  
Hepatic steatosis is another complication of insulin resistance that may 
progress over years with inflammation and fibrosis (non-alcoholic 
steatohepatitis). In adult patients with diabetes and obesity, 100% have mild 
steatosis, 50% have steatohepatitis, and 19% have cirrhosis32. The disease is 
usually silent over many years.  Serum levels of alanine aminotransferase, 
aspartate aminotransferase, alkaline phosphatase, and γ-glutamyltransferase are 
elevated and have been proposed as surrogate markers of hepatic fat 
accumulation33. The ratio of aspartate aminotransferase to alanine 
aminotransferase is usually less than 1, but this ratio increases as fibrosis 
advances. 
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Hypertension: 
Hyperinsulinemia can increase blood pressure by several mechanisms: 
via its effect to increase renal sodium absorption, via increased activity of the 
sympathetic nervous system, and via free fatty acids induced sensitivity to 
adrenergic stimuli and antagonized nitric oxide vasorelaxation34.   
Insulin resistance as an initiator of atherosclerosis: 
Studies of adults have shown that there is an association between insulin 
resistance and atherosclerosis. Increased thickness of the arterial carotid wall 
and an atherogenic dyslipidaemia profile are factors for increased risk of 
atherosclerosis. Importantly, hyperinsulinemia is an independent cardiovascular 
risk factor35.  The most predictive childhood risk factor was increased BMI. 
Coronary artery calcifications were also associated with increased blood 
pressure and decreased HDL cholesterol levels measured during Childhood36. 
Fatty streaks can be found in the aorta in children older than 3 year of age and 
in coronary arteries by adolescence37.  
The thickness of the carotid wall, a validated surrogate marker for 
atherosclerosis in teenagers and young adults, is sensitive to the intake of 
cholesterol, serum levels of cholesterol and triglycerides, BMI, smoking, 
hypertension, and fasting glucose38.Endothelial dysfunction is an early event 
preceding the formation of plaques, representing an early disease process of 
atherosclerosis that begins in childhood and is associated with insulin 
resistance and hyperinsulinemia39.  
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Inflammation, asthma, eczema, and impaired immunity: 
Insulin resistance syndrome and type 2 diabetes have increased markers 
of inflammation, such as C-reactive protein (CRP), erythrocyte sedimentation 
rates, and Tumor necrosis factor - α (TNF-α) levels. BMI correlates with levels 
of CRP40 and adiposity has been reported to be the major determinant of CRP 
levels in children. Leptin has been shown to up-regulate the production of 
proinflammatory cytokines, including TNF-α and interleukin-6 (IL-6), to 
increase phagocytosis by macrophages, and to increase T helper cell type 1 
(Th1) levels and suppression of Th2 cytokine production. 
Significant association between asthma and obesity has been noted, 
especially during puberty. One of the possible mechanisms is that obesity 
represents a proinflammatory state, and leptin levels influence Th1 cytokine 
responses. BMI correlated with the prevalence of asthma in both boys and girls. 
It was noted that girls who became obese between ages 6–11 year were 7 times 
more likely to develop new asthmatic symptoms at ages 11–13 years41. 
Hypoventilation and sleep apnoea. 
Excess body fat leads to a decline in the expiratory reserve volume, vital 
capacity, total lung capacity, and functional residual volume, probably due to 
the excess body mass, though others implicate excessive leptin levels42. 
Acanthosis Nigricans (AN) 
AN is a skin lesion that is widely used as a clinical surrogate of 
laboratory-documented insulin resistance/hyperinsulinemia, denoting a 
subgroup with a high risk for type 2 diabetes. The common sites of 
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involvement include axillae, posterior region of the neck, antecubital fossae, 
and groins. Less commonly, it involves the other flexural areas, umbilicus, 
submammary region, knuckles, elbows, and, in extreme cases, the entire skin. 
The severity of AN correlates well with the degree of insulin responses to 
insulin resistance. AN usually precede insulin resistance documentable by oral 
or intravenous glucose tolerance test. 
However, AN also persists into the decompensated phase of insulin 
resistance where insulin levels may be normal or low. High levels of insulin 
acting on both insulin and IGF-1 receptors present on keratinocytes inducing 
up-regulation of PPARβ/δ result in keratinocyte proliferation42. 
Hyperandrogenism and reproductive abnormalities 
Insulin resistance can present with overt virilisation or hirsutism, 
menstrual irregularity, persistent acne, scalp hair loss, hyperhidrosis, infertility, 
or precocious adrenarche in childhood. Menstrual irregularity and evidence of 
hyperandrogenism are associated with the polycystic ovarian disease. 
Hyperinsulinemia potentiates ovarian hyperandrogenism by enhancing pituitary 
LH secretion, potentiating ovarian 17- hydroxylase and 17,20-lyase activities, 
and suppressing blood sex hormone binding globulin (SHBG) and CBG levels 
and inhibiting both estradiol- and T4-stimulated SHBG production. 
Pseudo acromegaly 
Linear and acral growth is usually accelerated in insulin resistance and 
may present as pseudo acromegaly. Hyperinsulinemia promotes linear growth 
by activating skeletal IGF-I receptors, whereas low levels of insulin like growth 
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factor binding proteins(IGFBPs) can promote IGF-I action by allowing it to be 
freely and metabolically available. Ghrelin is known to stimulate GH secretion, 
and in obesity ghrelin levels are decreased. Direct action of leptin on bone 
growth can predispose to pseudoacromegaly43. Pseudoacromegaly is seen in the 
face of low plasma GH levels secretion so typical for obesity. 
Others 
 
Additional complications include focal (IgA type) segmental 
glomerulosclerosis, uric acid elevation, cholelilthiasis, pseudotumor cerebri, 
Blount’s disease, slipped capital femoral epiphysis, and psychological 
problems. 
MEASURING INSULIN ACTION IN VIVO: 
Insulin resistance is defined as an impaired ability of plasma insulin at 
usual concentrations to adequately promote peripheral glucose disposal, 
suppress hepatic glucose, and inhibit very low density lipoprotein (VLDL) 
output, but it can be inferred on strong clinical evidence and confirmed by 
insulin and glucose measurements made by fasting insulin/glucose screening, 
oral glucose tolerance tests (OGTT), the minimal model frequently sampled iv 
glucose tolerance test (FSIVGTT), and insulin/glucose clamp studies.  Fasting 
levels of insulin greater than 15 μU/ml, or insulin peak (post-OGTT) levels of 
more than 150 μU/ml and/or more than 75 μU/ml at 120 min of OGTT are 
hyperinsulinemic levels, which infer insulin resistance44. 
In normal individuals ingestion of a meal increases glucose and other 
secretogogues, including glucagon-like peptide 1, which act in concert to 
 29 
 
stimulate insulin secretion. Hyperinsulinemia in turn acts to renormalize the 
plasma glucose level by suppressing glucose production and increasing glucose 
utilization. Thus this ‘closed loop’ feedback system regulates plasma glucose 
concentration. In states of insulin resistance, the elevated insulin levels will be 
less able to normalize the glucose , therefore resulting in secondary stimulus to 
the β-cells and hyperinsulinemia. Because of the closed-loop relationship 
between insulin secretion and insulin action it is problematic to infer the 
existence of insulin resistance directly from a ‘closed loop' procedure like oral 
glucose tolerance test (OGTT)45. 
Hyperinsulinemic-euglycaemic clamp technique 
This technique uses an external feedback control to ‘open the loop’ 
between insulin secretion and sensitivity. By maintaining euglycaemia 
endogenous insulin secretion by pancreas is effectively‘clamped’46. 
Procedure:  
After overnight fasting venous catheters are inserted in right and left 
arms and 3 samples of blood to measure the basal insulin and glucose are taken 
at 5 min interval. Insulin infusion to be started at a rate of 1mU/kg/min and 
continued for 3 hours. The starting time is marked as ‘0’. An infusion of 20% 
glucose to be started at time 0. The plasma glucose level is measured at every 5 
minutes and glucose infusion is adjusted to maintain euglycaemia at 
5.6mmol/L. Insulin levels are measured usually after 2 hours of study at 140, 
160, and 180min. Usually it takes at least 2 hours to attain steady state of 
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euglycaemia. The rate of glucose infusion is considered a reflection of insulin 
sensitivity. 
The glucose clamp-derived index of insulin sensitivity (SIclamp)=M/(G*ΔI) 
M- The steady state of glucose infusion (mg/min) 
G- The steady state blood glucose concentration (mg/dl) 
ΔI- The difference between basal and steady state plasma insulin concentration 
(microunits/ml) 
SIclamp is usually expressed per kg body weight, per unit of surface area, or 
per unit fat free mass. 
Modified minimal frequently sampled intravenous glucose tolerance 
test: 
In the normal 24-h day the insulin-sensitive tissues are never exposed to 
steady-state conditions. After a meal, glucose and insulin levels are changing, 
the rate of glucose uptake lags in time behind the time courses of glucose and 
insulin. It may be preferable to measure insulin action from a dynamic 
relationship between glucose, the primary nutritive carbohydrate, insulin, the 
primary anabolic hormone, and the rate of glucose disposition. One approach to 
such a measurement is the frequently sampled intravenous glucose tolerance 
test with ‘minimal model’. Minimal model is a computer model that simply 
represents the plasma dynamics in a compact and accurate package47. 
Procedure :  
After 12 hours of fasting, 2 vascular accesses obtained by inserting 2 
flexible indwelling intravenous catheters through both ante cubital veins. One 
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is used for insulin administration; the other issued for glucose administration. 
Three samples of blood drawn for measuring fasting insulin and glucose at 10 
min interval. Glucose in the form of 25% dextrose is administered 
intravenously over one minute period at a dose of 0.3g/kg. After 20 min insulin 
is administered in the dose of 0.03u/kg. In next 3 hour period 30 blood samples 
are drawn for estimation of glucose and insulin at frequent intervals.  
These values are entered into MINMOAD computer programme (e.g.- 
version 3,Richard N.Bergeman 1994) to evaluate the following: 
• First phase insulin release (AIRglucose): reflects β cell functionality. 
• Insulin sensitivity index (Si) : Reflects ability of insulin to enhance effect of 
glucose to normalize its own concentration after injection. 
• Disposition index ( DI): Equals Si times AIR glucose. It reflects insulin 
sensitivity normalized to the degree of insulin resistance. 
On the basis of intravenous glucose tolerance testing, insulin release 
consists of two phases48. In individuals with type 2 diabetes, the second phase 
response is diminished, and the first phase response is almost absent. However, 
the first phase response decreases long before the development of type 2 
diabetes. AIR predicts the development of diabetes at a time when many 
subjects still have normal glucose tolerance. The DI is an excellent method to 
detect latent ß-cell defects, though hyperinsulinism documented by a high AIR 
is a predictor of the rate of increased fat mass. 
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Surrogate Measures of Insulin Sensitivity: 
Both hyperinsulinemic-euglycemic clamp technique and frequently 
sampled intravenous glucose tolerance test are time consuming, invasive, 
expensive, intensive, requires experienced personnel, and technically difficult 
to perform in obese young individuals. Here arises the need for simple but 
accurate methods for using in large populations. Indices of insulin sensitivity 
derived from fasting plasma glucose and insulin (HOMA-IR, QUICKI, FGIR, 
and fasting insulin) correlate strongly with Si assessed by the frequently 
sampled intravenous glucose tolerance test in obese children and adults17. 
Fasting Insulin: 
There is curvilinear relationship between fasting insulin and insulin 
sensitivity. If insulin sensitivity is low, fasting insulin will be elevated. The 
fasting insulin concentration will not represent an accurate reflection of insulin 
sensitivity comparing individuals or groups for whom β- cell function is not 
identical. When we compare fasting insulin between normal individuals and 
individuals with impaired glucose tolerance, the latter group is not only insulin 
resistant, but characterized by a β-cell defect of at least 50%. 
 
Homeostasis model assessment index (HOMA-IR): 
This is based on fasting insulin and fasting glucose values .This is 
calculated by following formula 
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In non-diabetic individuals plasma glucose differs little compared to 
fasting plasma insulin levels. In non-diabetic subjects HOMA-IR values are 
proportional to the fasting insulin concentration. HOMA-IR will not reflect 
insulin sensitivity accurately in non-diabetic subjects with differing β-cell 
function. 
Quantitative Insulin Check Index (QUICKI):  
It is equal to the inverse of the sum of the logarithms of fasting plasma 
glucose and fasting plasma insulin. 
         QUICKI= 1/ (log fasting insulin(micromol/ml)+log fasting 
glucose(mg/dl) ) 
Despite the logarithmic transformation, QUICKI values exhibit 
nonlinear proportionality to fasting plasma insulin and may underestimate 
insulin resistance in a population with a latent decrease in β-cell function. 
Fasting Glucose insulin Ratio (FIGR):  
The fasting glucose-to insulin ratio has also been proposed as a useful estimate 
of insulin sensitivity. 
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Insulin Sensitivity Based Upon the OGTT:  
There are insulin sensitivity indices based on oral glucose tolerance test 
like Stumvoll index and Matzuda index. It is clear that a correlation between 
proposed OGTT-derived indices and clamp-derived insulin sensitivity may 
exist. However, the OGTT-derived indices contain endogenous insulin 
response in their calculation and it cannot be excluded that reported 
correlations reflect islet cell response rather than insulin sensitivity.  
As OGTT-based methods reflect secretion rather than sensitivity, 
application of the OGTT methods to subjects with impaired β-cell secretory 
capacity(e.g., those with impaired glucose tolerance, type 2 diabetes) would 
incorrectly underestimate insulin resistance as post load hyperinsulinemia 
would be reduced. Another limitation is poor reproducibility49. This is due to 
high day-to-day variability in gastrointestinal function (gastric functioning, 
absorption and G.I hormones). It is concluded that variations in OGTT cannot 
be readily interpreted to reflect changes in insulin sensitivity but rather changes 
in gastric emptying, insulin secretion, etc. At this juncture, it may not possible 
to support the use of the OGTT for assessing insulin resistance 
TREATMENT:  
In children, insulin resistant is usually well compensated by 
hyperinsulinemia, but there may be progressive failure of compensation 
through puberty with rising glucose and triglyceride levels. Even compensated 
hyperinsulinemia can lead to numerous complications from fatty liver and 
atherosclerosis to increased cancer risk. 
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Diet and behavioural therapy: 
The child with insulin resistant syndrome should be aggressively treated 
by involvement in an exercise program, such as walking or swimming for 30–
40 min most days of the week, because exercise provokes glucose entry into 
muscle without the involvement of insulin. Calorie and especially carbohydrate 
restriction is the key to reduce weight. However, where there is also an 
increased level of triglycerides, restriction of animal fats should be imposed.  
Behavioural therapy and metformin have been proven safe and effective in 
improving insulin sensitivity in paediatric patients50. 
Family-based behavioural interventions for obese children are safe and 
useful treatments for paediatric obesity. These interventions have been 
associated with reductions in total cholesterol, increases in HDL cholesterol, 
reductions in insulin resistance, and return of ovulatory cycles 
Pharmacologic therapy: 
Metformin is the drug of choice for insulin resistance syndrome. 
Metformin has various mechanisms of action in insulin resistance. It enhances 
insulin binding to insulin receptor with augmented phosphorylation and 
tyrosine kinase activity of the receptor51. It is effective even in cases of insulin 
receptor mutations. It increases peripheral utilization of glucose through 
potentiating the phosphoinositol 3-kinase after engagement of the insulin 
receptor, increasing translocation of the glucose transporters GLUT1 and 
GLUT4 isoforms to cell membrane in different tissues; increases the activity of 
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adenosine monophosphate kinase in muscle and liver. It increases IGFBP-1; 
decreases endothelin-1, a marker of vasculopathy; and decreases hepatic 
glucose output. Metformin down-regulates TNF-α expression and uncoupling 
protein-2 mRNA concentrations in liver, thus decreasing hepatic lipid 
biosynthesis. Metformin is safe for the treatment of insulin resistance syndrome 
in paediatric patients52. 
The PPAR-γ (thiazolidenediones) agonists are a group of ligand 
activated transcription factors that govern energy metabolism, cell 
proliferation, and inflammation53. PPAR-γ agonists are effective at insulin 
sensitization, but are less useful in supporting weight loss. 
Lipid-lowering agents like Fibrates lower triglyceride levels, as 
mediated through the PPAR-γ transcription factor, mainly in liver, where it has 
an important role in FA oxidation, gluconeogenesis, and amino acid 
metabolism. Pre-treatment of endothelial cells with a PPAR-γ agonist 
(fenofibrate) reduced markers of inflammation such as vascular cell adhesion 
molecule-1 expression, CRP, fibrinogen, and IL-6.  
Statins inhibit 3-hydroxy-3- methylglutaryl-CoA reductase, the rate-
limiting enzyme synthesis of cholesterol. To compensate for decreased 
synthesis and to maintain cholesterol homeostasis, hepatocytes increase the 
expression of LDL receptors, which increases the uptake of plasma LDL, the 
main carrier of extracellular cholesterol, resulting in lower plasma LDL 
concentrations. Decreased plasma LDL levels reduce the progression of 
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atherosclerosis and may even lead to the regression of pre-existing 
atherosclerotic lesions. Statins have important immunomodulatory effects as 
well and are able to decrease the recruitment of monocytes and T cells into the 
arterial wall and inhibit T cell activation and proliferation 54. 
Low doses of aspirin inactivate the enzyme cyclooxygenase, which 
catalyses the conversion of arachidonic acid to prostaglandins G2 and H2. 
These prostaglandins are precursors of thromboxane, a potent platelet 
proaggregant and vasoconstrictor. Low doses of enteric coated aspirin is 
preferred. Aspirin may have a place in dyslipidaemia children with insulin 
resistance syndrome prone to pancreatitis. 
Surgery 
Restrictive surgical procedures based on an adjustable silicone band 
placement around a stomach fundal pouch can create a functional partition of 
the stomach. Whereas restrictive procedures are effective in reducing intake of 
solid foods, high consumption of more liquid high calorie foods may prevent 
weight loss55 Intestinal bypass surgery in children should probably only be used 
only in cases of potentially life threatening complications such as sleep apnoea. 
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REVIEW OF LITERATURE 
Milagros G Huerta et al56 conducted a study to determine whether 
obese children exhibit dietary or serum magnesium deficiency and its potential 
association with insulin resistance. 24 obese non diabetic children and 24 sex 
and puberty matched subjects were included in the study and blood samples 
were taken for blood glucose, serum insulin and magnesium. Dietary 
assessment regarding magnesium intake was done using a food questionnaire. 
Insulin resistance assessed using HOMA-IR and QUICKI. 
 On analysis authors found that serum magnesium levels was 
significantly lower in obese children (0.748 ± 0.015 mmol/l, means±SE) 
compared with lean children (0.80±0.012 mmol/l) (P=0.009). Serum 
magnesium was inversely correlated with fasting insulin (rs=0.36 [95% CI-0.59 
to-0.08]; P =0.011) and positively correlated with quantitative insulin 
sensitivity check index (QUICKI) (0.35 [0.06–0.58]; P = 0.015). Dietary 
magnesium intake was significantly lower in obese children (obese: 0.12 ± 
0.004 vs. lean: 0.14 ± 0.004 mg/kcal; P = 0.003). Dietary magnesium intake 
was inversely associated with fasting insulin(-0.43 [--0.64 to -0.16];  P = 0.002) 
and directly correlated with QUICKI (0.43 [0.16–0.64]; P =0.002). 
Authors concluded by saying that there is an association between 
magnesium deficiency and insulin resistance in obese children and magnesium 
supplementation or increased intake of magnesium containing foods may 
prevent against the development of Type 2 Diabetes Mellitus in obese children. 
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Ali M. Zaakouk et al57 conducted a study in 2013 to evaluate serum 
magnesium status in obese children and to correlate magnesium level with the 
degree of obesity and lipid profile. 50 obese children and 50 healthy non obese 
controls aged 2-16 years were included in the study and serum magnesium and 
lipid profile were measured. 
 Authors found that obese children compared to lean healthy controls had 
low serum magnesium and HDL with elevated levels of total cholesterol, 
triglycerides, LDL and high levels of systolic and diastolic blood pressure. 
Serum magnesium showed a significant, strong inverse correlation with the 
degree of obesity (r =-0.8, p<0.001); moderate inverse correlation with total 
cholesterol and LDL-cholesterol; and non-significant correlation with 
triglycerides and HDL-cholesterol. The degree of obesity showed a significant, 
moderate positive correlation with total cholesterol and LDL-cholesterol and a 
non-significant correlation with triglycerides and HDL-cholesterol. 
Authors concluded that Serum magnesium levels are inversely 
correlated with the degree of obesity, and is related to an unfavourable serum 
lipid profile in obese children and adolescents, who also show a trend to higher 
systemic blood pressure 
Bipin Jose et al58 conducted a cross sectional study to determine 
whether overweight children have lower serum concentration and lower dietary 
intake of magnesium compared to those with normal weight; and to study the 
correlation of serum magnesium levels with components of metabolic 
syndrome in children and adolescents. 55 overweight and 53 normal weight 
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individuals aged 4-14 years were included and serum magnesium, glucose, 
lipid profile, insulin levels were measured. Dietary intake of magnesium was 
calculated. 
On analysis authors found that the serum magnesium levels were 
significantly lower in overweight (2.12 ± 0.33 mg/dL) compared to normal 
weight group (2.56 ± 0.24 mg/dL, P<0.001), while the dietary intake of 
magnesium (adjusted for calorie intake) was higher in overweight group (0.20 
± 0.06 mg/ kcal) compared to normal weight (0.17 ± 0.05 mg/kcal; P= 0.005). 
Serum magnesium levels were inversely correlated with body mass index, 
systolic blood pressure, diastolic blood pressure, waist circumference and 
fasting insulin levels. 
Authors concluded that serum magnesium levels were significantly 
lower in overweight children compared to those with normal weight in spite of 
a higher dietary intake. 
Guerrero-Romero F et al59 conducted a cross sectional population 
based study to know the relation between serum magnesium and Metabolic 
Syndrome (MS). 192 individuals with metabolic syndrome (defined as per 
criteria) and 384 age and gender matched disease free control subjects were 
included in the study. 
 On analysis, authors found that low serum magnesium levels were 
present in 126 (65.6%) and 19 (4.9%) individuals with and without MS, 
p<0.00001 and the mean serum magnesium levels among subjects with MS 
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was 1.8+/-0.3 mg/dl, and among control subjects was 2.2+/-0.2 mg/dl, 
p<0.0000. 
 Authors concluded by saying that low serum magnesium is strongly 
related to metabolic syndrome. 
 Celik N et al60 did a study to investigate the relation between serum 
magnesium levels with obesity and Insulin Resistance (IR) in childhood. Study 
was designed to include 117 obese children and 86 controls. Obese children 
were split into two groups IR+ and IR-. After an overnight fasting levels of 
serum insulin, glucose and magnesium were obtained. 
 On analysis, it was found that serum magnesium levels were lower in 
IR+ obese group than controls (p=0.014) and there was also a positive 
correlation between serum magnesium levels and body mass index-standard 
deviation score (BMI-SDS) (r = -0.28, p = 0.03) in the IR (-) obese group. 
 The study was concluded with the evidence that low serum magnesium 
level may lead on to the development of insulin resistance in obese children. 
 Cenge Yakinci et al61 did a study to know the relationship between 
levels of serum copper, zinc and magnesium with obesity. Study included 41 
obese children and 41 non obese controls bot aged between 7-11 years of age. 
 On analysis , the results of the study was that the serum levels of zinc 
and copper were significantly higher in obese group (zinc-mean value 102.40 ± 
2.78 µg/dL) (copper-mean value 132.34 ±1.79 µg/dL) compared to controls 
(zinc-mean value 80.49 ± 2.98 µg/dL; P < 0.01) (copper-mean value 107.58 ± 
1.62 µg/dL, P < 0.01),whereas serum magnesium levels were significantly  
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lower in obese group (mean value 1.78 ± 0.03 mg/dL) compared to controls 
(mean value 2.14 ± 0.04 mg/dl P < 0.01) 
 Syed Awais ul Hassan et al62 conducted a case control study to 
determine the serum levels of magnesium between obese and overweight 
children with normal weight children. Study was designed to include 70 
children in the obese and overweight category and 70 children in the normal 
weight group. 
 On analysis authors found that the serum magnesium levels were 
significantly lower in the overweight and obese group (2.08 ± 0.211 mg/dl) as 
compared to the normal weight group (2.55 ± 0.155 mg/dl, p<0.001). 
 Authors concluded by saying that mean serum magnesium levels were 
lower in obese and overweight group and effect of magnesium supplementation 
in weight reduction needs to be studied by further studies. 
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STUDY JUSTIFICATION 
 
Various studies have shown significant relationship between serum 
magnesium with insulin resistance and with other markers of metabolic 
syndrome. However such data of association between serum magnesium with 
insulin resistance in Indian population is lacking even though there are several 
Indian studies proving that obesity is associated with low serum magnesium 
This study was designed in a such a way to include both obese and overweight 
subjects and to determine the levels of magnesium between obese and 
overweight children in one group with normal weight children in another 
group. If we prove the significant association between low magnesium levels 
with insulin resistance in a population where obesity is on the rise, there arises 
a question of whether magnesium supplementation in obese children prevents 
insulin resistance thereby prevent the development of type 2 Diabetes Mellitus. 
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AIM AND OBJECTIVES 
Aim: 
To study the relationship between serum magnesium levels and insulin 
resistance in obese children aged 5 – 12 years. 
Objectives: 
Primary objective: 
To determine whether overweight and obese children have low serum 
magnesium compared to age and sex matched controls. 
Secondary objective: 
To correlate whether low serum magnesium is associated with insulin 
resistance in obese and overweight children aged 5-12 years. 
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MATERIALS AND METHODS 
Study Design: 
Cross sectional study – case control type 
Study period: 
Oct 2016 to Aug 2017 
Study place: 
Paediatric Endocrine Division, Institute of Child Health & Hospital for 
Children, Chennai – 8. 
Inclusion Criteria: 
 Cases: Children in the age group of 5-12 years, who satisfy the criteria 
for overweight/obesity as per revised IAP growth charts 2015 
 Controls: Age and sex matched healthy controls attending school health 
cell 
Exclusion Criteria: 
Children with secondary causes of obesity (e.g., Genetic syndrome Cushing 
syndrome, hypothyroidism) 
Diabetes mellitus 
Children with medical conditions predisposing to hypomagnesaemia 
(gastroenteritis, chronic kidney disease and chronic liver disease) 
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Children who are on long term drug therapy especially with those drugs which 
are going to alter serum magnesium (e.g. diuretics, amphotericin etc) were 
excluded. 
Sample Size: 
Taking the pooled variation of magnesium levels in cases and controls of the 
previous Indian study58, expecting a mean difference of 0.5 between cases and 
controls with an α error of 0.05 and power of 0.8, calculated sample size was 
found to be between 48 to 60 in each arm. 
1:1 ratio of 56 overweight and obese children and 56 age and sex matched lean 
controls were included in the study. 
Ethical committee approval: 
Study was undertaken after obtaining approval from ethical committee 
Informed written consent: 
Informed written consent from all parents/guardian of the subjects was 
obtained. 
Case Definition: 
Overweight and obesity are defined as per revised IAP growth charts 2015 as8 
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Overweight – BMI falling between 23 adult equivalent centile and 27 adult 
equivalent centiles. 
Obesity – BMI above 27 adult equivalent centiles. 
Manoeuvre: 
After obtaining informed consent, subjects who were included in the study was 
admitted in paediatric medical ward and was subjected to the following. 
History: 
Detailed clinical history was undertaken from the subjects recruited into the 
study. The following history was obtained. 
Duration of obesity 
History of drug intake 
Family history of obesity, diabetes mellitus, dyslipidaemia, hypertension 
Clinical examination: 
Detailed clinical examination was done in all children which includes 
measurement of weight, height, waist circumference, blood pressure.  
Anthropometric measurements: 
Weight: 
Weight was measured using a digital weighing scale to the nearest of 0.1 Kg. 
The following precautions were taken while measuring weight. 
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 Outer clothing and shoes removed 
  The scale is placed in the zero position before the child steps on the 
scale. 
 The child made to stand still with both feet 15 cms apart in the center of 
the platform. 
 The weighing scale was regularly checked with known standard 
weights. 
Height: 
Height was measured using wall mounted stadiometer to the nearest of 0.5 cm. 
This device has a flat vertical surface on which a measuring scale is attached. It 
also has a moveable headpiece and a permanent surface to stand. The following 
precautions were undertaken while measuring height. 
 Child made to stand erect with Shoes or slippers removed and shoulders 
at level, hands at sides, thighs together, and weight evenly distributed 
between both the feet. 
  Child's feet placed flat on the floor with heels comfortably together  
 Child was asked to adjust the angle of his/her head by moving the chin 
up or down in order to align the head in the Frankfurt plane(The 
Frankfurt plane-imaginary line from the lower margin of the eye socket 
to the notch above the tragus of the ear). The plane is viewed from the 
side and at the eye level of the child. 
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  Headpiece lowered until it touches firmly over the crown of the head 
and at right angle to the measurement surface 
  
                                          
Waist circumference: 
Waist circumference was measured using non elastic tape at the midpoint of 
iliac crest and lower border of rib cage to the nearest of 0.1 cm. 
Blood pressure: 
Blood pressure measured using mercury sphygmomanometer by ausculto-
palpatory method.  The following precautions were undertaken while 
measuring blood pressure 
 The children were asked to remove all clothing that covers the location 
of cuff placement  
 Measurement done after 5 minutes rest 
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 Comfortably seated, with the legs uncrossed, and the back and arm 
supported, such that the middle of the cuff on the upper arm is at the 
level of the right atrium and are instructed to relax as much as possible 
and to not talk during the measurement procedure 
 Appropriate sized cuffs were used. 
Values more than 90th centile for age and sex was considered high. 
BMI calculation: 
Based on weight and height BMI was calculated using the formula 
BMI = weight in kilograms(Kg)/height in metres squared(m2) 
BMI was plotted in revised IAP growth charts 2015 and children were 
classified accordingly. 
Laboratory investigations: 
After an overnight fasting for 12 hours 5 ml venous blood was drawn and 
following parameters were measured 
 Fasting blood sugar 
 Fasting serum insulin 
 Fasting lipid profile(serum cholesterol, serum triglycerides, HDL) 
 Serum sodium, potassium, calcium 
 SGOT/SGPT 
 Serum magnesium 
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Plasma glucose was measured using glucose oxidase-peroxidase method 
in an automated analyzer.  
Serum concentrations of Total cholesterol was measured by CHOD 
POD method, HDL measured by direct assay method and Triglycerides were 
measured by GPO method.  
Serum magnesium was measured using photometric end point assay 
method. Machine used was cobas c311 fully automated chemistry analyzer.  
Serum insulin was measured using eCLIA- electro chemiluminiescence 
radio immuno assay. Machine used was cobas c411 fully automated immune 
analyzer 
Insulin resistance index: 
The HOMA-IR, QUICKI, and FGIR were derived as estimates of 
insulin resistance.  
The HOMA index was calculated as fasting insulin concentration (μu/ 
ml) x fasting glucose concentration (mmol/L) / 22.5. 
The QUICKI was calculated as1/ [log fasting insulin concentration (μu/ 
ml) + log glucose concentration (mg/dL)].  
FGIR is calculated as fasting glucose (mg/dl)/fasting insulin (μu/ ml). 
 
STATISTICAL ANALYSIS: 
All the descriptive statistics, frequency histograms and bar charts were 
created using Gnumeric spreadsheet (version: 1.12.28), a light weight spread 
sheet developed by Gnome open source project.  
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 Parametric test was done for continuous variables. Non parametric test 
like Wilcoxon rank sum test was done for categorical variable. 
 Correlation of serum magnesium with HOMA-IR, QUICKI, FGIR, 
fasting serum insulin, BMI was done using Pearson’s correlation coefficient. 
All parametric and non-parametric tests and tests for categorical data 
were done in R programming language (R version 3.2.3 (2015-12-10) 
– “Wooden Christmas-Tree” Copyright © 2015 The R Foundation for 
statistical computing). The computing platform was x86_64-Arch-Linux-gnu 
(64-bit). 
 
ETHICAL CONSIDERATIONS: 
 The study was commenced after the ethical committee clearance. 
Informed consent was obtained from parent. Strict confidentiality was 
maintained while analysing and presenting the data. 
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RESULTS 
Age distribution in cases and controls: 
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POPULATION MEAN±2 S.E OBSERVED 
MEAN 
DIFFERENCE 
P VALUE 
CASES 105.41±24.11  
0.23 
 
0.9592 CONTOLS 105.18±23.78 
 
Mean age (months) in cases (105.41) is nearly equal to the mean age in 
controls (105.18). Observed mean difference in age (0.23) between cases and 
controls was not statistically significant. P value=0.9592 
Sex distribution in cases and controls: 
Among 56 children in the cases group 32(57%) children were male and 
24(43%) children were female. 
Among 56 children in controls group 33(59%) children were male and 
23(41%) children were female. 
POPULATION MALE FEMALE 
CASES 32 24 
CONTROLS 33 23 
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M:F ratio in cases=1.33:1and M:F ratio in controls=1.43:1.  
Two sample test for equality of proportion with continuity correction. P = 1 
The difference in sex distribution among these two group was statistically not 
significant . 
 56 
 
Family History of Obesity in cases and controls: 
Among 56 children in cases group 25(45%) children had positive family 
history of obesity in contrast to 13(23%) children who had positive family 
history of obesity in control group. 
POPULATION POSITIVE FAMILY 
HISTORY OF 
OBESIY 
P VALUE 
CASES 25  
P=0.028 CONTROLS 13 
On analysis with student t test family history of obesity was statistically 
significant between the cases and controls. p=0.028. 
Family History of diabetes mellitus in cases and controls: 
Among 56 children in cases group 28(50%) children had positive family 
history of diabetes in contrast to 10(18%) children who had positive family 
history of diabetes in control group. 
POPULATION POSITIVE FAMILY 
HISTORY OF 
DIABETES 
P VALUE 
CASES 28  
P=<0.001 CONTROLS 10 
 
On analysis with student t test family history of diabetes was statistically 
significant between the cases and controls. p=<0.001. 
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Family History of hypertension in cases and controls: 
Among 56 children in cases group 6(11%) children had positive family 
history of hypertension in contrast to 5(9%) children who had positive family 
history of hypertension in control group. 
 
POPULATION POSITIVE FAMILY 
HISTORY OF 
HYPERTENSION 
P VALUE 
CASES 6  
P=1 CONTROLS 5 
 
On analysis with Fischer test family history of hypertension was not 
statistically significant between the cases and controls. p=1 
Family History of thyroid disorders in cases and controls: 
Among 56 children in cases group 2(3.5%) children had positive family 
history of thyroid disorders in contrast to 0 children who had positive family 
history of thyroid disorders in control group. 
 
POPULATION POSITIVE FAMILY 
HISTORY OF 
THYROID 
DISORDER 
P VALUE 
CASES 2  
P=0.5 CONTROLS 0 
 
On analysis with Fischer test family history of thyroid disorder was not 
statistically significant between the cases and controls. p=0.5. 
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Adiposity in cases and controls: 
BMI in cases and controls: 
Student t analysis of BMI was done between cases and controls. 
POPULATION MEAN±2 S.E OBSERVED 
MEAN 
DIFFERENCE 
P VALUE 
CASES 24.87±4.3  
10.76 
 
<0.001 CONTOLS 14.11±1.46 
 
The mean BMI of case group (24.87) is higher than the control group 
(14.11). The observed mean difference in BMI  between cases and controls  
(10.76) is statistically significant. p=<0.001. 
Waist circumference in cases and controls: 
Student T test analysis of Waist circumference was done between cases 
and controls for determining the statistical significance. 
POPULATION MEAN±2 S.E OBSERVED 
MEAN 
DIFFERENCE 
P VALUE 
CASES 77.88±9.05  
25.25 
 
<0.001 CONTOLS 52.63±4.91 
The mean waist circumference(cm) of case group (77.88) was higher 
than the control group(52.63). The observed mean difference in waist 
circumference between cases and controls  (25.25) was statistically significant. 
p=<0.001. 
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Except for adiposity, family history of obesity and diabetes mellitus, the 
baseline variables between cases and controls was comparable to each other. 
Table : Baseline characteristics between cases and controls 
VARIABLES CASES CONTROLS P VALUE 
MEAN AGE(MONTHS) 105.41±24.11 105.18±23.78 0.9592 
SEX M/F 32/24 33/23 1 
NO OF CHILDREN 
WITH FAMILY H/O 
OBESITY 
25 13 0.028 
NO OF CHILDREN 
WITH FAMILY H/O 
DIABETES 
28 10 <0.001 
NO OF CHILDREN 
WITH FAMILY H/O 
HYPERTENSION 
6 5 1 
NO OF CHILDREN 
WITH FAMILY H/O 
THYROID 
DISORDERS 
2 0 0.5 
MEAN BMI 24.87±4.3 14.11±1.46 <0.001 
MEAN WAIST 
CIRCUMFERENCE(cm) 
77.88±9.05 52.63±4.91 <0.001 
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Blood pressure in cases and controls: 
Mann Whitney U test was done between the cases and controls for 
analysis of blood pressure. 
Systolic Blood pressure in cases and controls: 
Systolic BP (mm Hg) Median (Inter Quartile range -IQR) in cases100 ( 
90-110) was found to be not statistically significant when compared with 
control group median( IQR) 100(90-100). p=0.064 
POPULATION MEDIAN(IQR) P VALUE 
CASES 100(90-110)  
0.064 CONTROLS 100(90-100) 
 
Diastolic Blood pressure in cases and controls: 
Diastolic BP (mm Hg) in median (IQR) in cases 70 ( 60-70) was found 
to be not statistically significant when compared with control group median 
IQR 65(60-70). p=0.30 
POPULATION MEDIAN(IQR) P VALUE 
CASES 70(60-70)  
0.30 CONTROLS 65(60-70) 
 
 61 
 
Serum triglycerides in cases and controls: 
POPULATION MEAN±2 S.E OBSERVED 
MEAN 
DIFFERENCE 
P VALUE 
CASES 124.68±55.16  
33.88 
 
<0.001 CONTOLS 90.80±23.60 
 
On student t analysis the mean serum triglyceride level (mg/dl) of case 
group (124.68) was higher than the control group (90.80). The observed mean 
difference in serum triglycerides level between cases and controls (33.88) was 
statistically significant. p=<0.001. 
Serum cholesterol in cases and controls: 
POPULATION MEAN±2 S.E OBSERVED 
MEAN 
DIFFERENCE 
P VALUE 
CASES 157.02±32.38  
30.56 
 
<0.001 CONTOLS 126.46±25.06 
 
On student t analysis the mean serum cholesterol level (mg/dl)  of case 
group (157.02) was higher than the control group(126.46). The difference in 
mean serum cholesterol level between cases and controls (30.56) was 
statistically significant. p=<0.001. 
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Serum HDL in cases and controls: 
POPULATION MEAN±2 S.E OBSERVED 
MEAN 
DIFFERENCE 
P VALUE 
CASES 39.54±8.09  
5.53 
 
<0.001 CONTOLS 45.07±4.31 
 
On student t analysis the mean serum HDL (mg/dl) level of case group 
(39.54) was lower than the control group (45.07). The difference in mean 
serum HDL level between cases and controls (5.53) was statistically 
significant. p=<0.001. 
Electrolytes in cases and controls: 
Serum sodium in cases and controls: 
POPULATION MEDIAN(IQR) P VALUE 
CASES 138(136-139)  
<0.001 CONTROLS 136(134-137) 
  
On analysis with Wilcoxon rank sum test, serum sodium (Meq/l) 
between cases median (IQR) 138(136-139) and controls 136(134-137) was 
statistically significant. p=<0.001 
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Serum Potassium in cases and controls: 
POPULATION MEAN±2 S.E OBSERVED 
MEAN 
DIFFERENCE 
P VALUE 
CASES 4.19±0.22  
0.04 
 
=0.406 CONTOLS 4.23±0.23 
 
The mean serum potassium level (Meq/l) of case group (4.19) was lower 
than the control group(4.23). The difference in mean serum potassium level 
between cases and controls (0.04) was not statistically significant. p=0.406 
Serum Calcium in cases and controls: 
POPULATION MEAN±2 S.E OBSERVED 
MEAN 
DIFFERENCE 
P VALUE 
CASES 9.13±0.36  
0.09 
 
0.193 CONTOLS 9.22±0.30 
The mean serum calcium level (mg/dl) of case group (9.13) was lower 
than the control group(9.22). The difference in mean serum calcium level 
between cases and controls (0.09) was not statistically significant. p=0.193 
Liver enzymes in cases and controls: 
Liver enzymes SGOT and SGPT was analysed between cases and controls. 
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SGOT in cases and controls: 
POPULATION MEAN±2 S.E OBSERVED 
MEAN 
DIFFERENCE 
P VALUE 
CASES 24.69±6.73  
2.30 
 
0.054 CONTOLS 22.39±5.76 
The mean serum SGOT of case group (24.69) was higher than the 
control group (22.39). The difference in mean serum SGOT level between 
cases and controls (2.30) was not statistically significant. p=0.054. 
SGPT in cases and controls: 
POPULATION MEDIAN(IQR) P VALUE 
CASES 20(17.50-26) 0.051 
 
CONTROLS 18(16-22) 
  On analysis with Wilcoxon rank sum test, serum SGPT between cases 
and controls was not statistically significant. p=0.051 
Fasting serum glucose in cases and controls: 
POPULATION MEAN±2 S.E OBSERVED 
MEAN 
DIFFERENCE 
P VALUE 
CASES 82.52±11.79  
3.98 
 
0.0610 CONTOLS 78.54±10.44 
The mean serum fasting glucose level of case group (82.52) was higher 
than the control group (78.54). The difference in mean serum glucose level 
between cases and controls (3.98) was not statistically significant. p=0.0610. 
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Fasting serum insulin in cases and controls: 
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POPULATION MEDIAN(IQR) P VALUE 
CASES 19.64(13.97-27.89)  
<0.001 
CONTROLS 7.50(5.21-10.39) 
 
On analysis with Wilcoxon rank sum test, fasting serum insulin between 
cases and controls was statistically significant. p=<0.001 
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Serum magnesium in cases and controls: 
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POPULATION MEAN±2 S.E OBSERVED 
MEAN 
DIFFERENCE 
P VALUE 
CASES 2.04±0.23  
0.25 
 
<0.001 CONTOLS 2.29±0.15 
 
The mean serum magnesium level (mg/dl) among cases group (2.04) 
was lower than the control group (2.29). The difference in mean serum 
magnesium level between cases and controls (0.25) was statistically significant. 
p=<0.001. 
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Insulin sensitivity indexes in cases and controls: 
HOMA-IR in cases and controls: 
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POPULATION MEDIAN(IQR) P VALUE 
CASES 4(2.50-5.92)  
<0.001 CONTROLS 1.35(1.00-2.00) 
 
On analysis with Wilcoxon rank sum test, HOMA-IR between cases and 
controls was statistically significant. p=<0.001 
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QUICKI in cases and controls: 
 
POPULATION MEDIAN(IQR) P VALUE 
CASES 0.31(0.30-0.33)  
<0.001 CONTROLS 0.36(0.34-0.38) 
 
On analysis with Wilcoxon rank sum test, QUICKI between cases and 
controls was statistically significant. p=<0.001 
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FGIR in cases and controls: 
 
POPULATION MEDIAN(IQR) P VALUE 
CASES 4.12(2.95-5.73)  
<0.001 CONTROLS 9.80(7.51-15.21) 
 
On analysis with Wilcoxon rank sum test, FGIR between cases and 
controls was statistically significant. p=<0.001 
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Correlation between serum magnesium levels and HOMA-IR: 
 
y=-0.0712063x+2.36934 
R2=0.592871 
r=0.76998 
p=<0.001 
There is a significant negative correlation between serum magnesium and 
HOMA-IR. 
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Correlation between serum magnesium levels and QUICKI: 
 
y=7.58662x-0.336849 
R2=0.652959 
r=0.80806 
p=<0.001 
There is a significant positive correlation between serum magnesium and 
QUICKI. 
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Correlation between serum magnesium levels and FGIR: 
 
y=0.0732802x+1.70602 
R2=0.518441 
r=0.72003 
p=<0.001 
There is a significant positive correlation between serum magnesium and 
FGIR. 
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Correlation between serum magnesium levels and fasting serum insulin: 
 
y=-0.0174168x+2.42478 
R2=0.601634 
r=0.77565 
p=<0.001 
There is a significant negative correlation between serum magnesium and 
fasting serum insulin. 
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Correlation between serum magnesium levels and BMI: 
 
y=-0.0311319x+2.81866 
R2=0.34955 
r=0.59123 
p=<0.001 
There is a significant negative correlation between serum magnesium 
and BMI. 
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Intragroup comparison: 
Intragroup comparison between 13 overweight and 43 obese children were 
made. M:F  in obese group=1.38:1 and in overweight group=1.16:1.On analysis 
of variables between obese and overweight following observations were made. 
VARIABLES OBESE OVERWEIGHT P VALUE 
BMI 26.27±3.90 20.37±1.61 <0.001 
Waist 
circumference(cm) 
79.79±8.78 71.54±6.96 0.002 
Magnesium(mg/dl) 2.00±0.24 2.18±0.075 <0.001 
Fasting 
insulin(micro 
units/ml) 
23.8(17.9-30.38) 14.18(12.00-14.83) <0.001 
HOMA-IR 4.4(3.35-6.6) 2.5(2.3-3.30) 0.003 
QUICKI 0.31(0.29-0.32) 0.33(0.32-0.34) 0.004 
FGIR 3.33(2.87-4.52) 6.07(5.07-6.41) 0.001 
 
Statistical significance was present for BMI, waist circumference, fasting 
insulin, serum magnesium, HOMA-IR, QUICKI, FGIR between obese nad 
overweight individuals. 
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DISCUSSION 
Magnesium, an important intracellular cation has a pivotal role in the 
regulation of obesity as proved by various studies which showed that obese and 
overweight children had low serum magnesium compared to lean controls. 
Magnesium by acting as a cofactor for the enzymes in carbohydrate and lipid 
pathways has a role in insulin resistance. Huerta MG et al56 in their study 
proved the association between low serum magnesium and insulin 
resistance(HOMA-IR and QUICKI). They also showed the association between 
dietary magnesium intake with insulin resistance. Serum magnesium role in 
other components of metabolic syndrome apart from insulin resistance has been 
proved in a study conducted by Ali M. Zaakouk et al57, where the researchers 
concluded by saying that serum magnesium is inversely correlated with total 
cholesterol, triglycerides, LDL and positively correlated with HDL. Bipin Jose 
et al58 in their study showed the association between serum magnesium with 
systolic BP, diastolic BP, BMI, WC and fasting insulin. This is the first study 
done in Indian children where association of serum magnesium with BMI, 
fasting insulin, indexes of insulin resistance was analysed. The study was 
carried out in children attending Paediatric endocrine OPD of Institute of child 
health & hospital for children, Chennai with a motive of proving the 
association between serum magnesium with obesity and insulin resistance in a 
population where obesity is on the rising trend. 
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In our study 56 children aged 5-12 years belonging to either obese or 
overweight category as per IAP growth charts were compared with 56 normal 
children. Mean age of children in cases was 105.41 months and 105.18 in 
control group. P value=0.9592 statistically not significant. Sample size of our 
study was similar to a study done by Bipin Jose et al58. Out of 56 children 43 
children were in the obese group and the rest 13 belong to the overweight 
group. To the best of our knowledge this is the first study designed in such a 
way to include both obese and overweight cases so that intragroup comparison 
of variables between overweight and obese children can be made. 
M: F in cases was 1.33:1 and 1.43:1 in controls. p value=1, statistically 
not significant. 
Family history of obesity, diabetes Mellitus, thyroid disorders and 
hypertension was taken into account and analysed between the cases and 
controls. Family history of obesity and diabetes mellitus showed statistical 
significance between cases and controls whereas there was no statistical 
significance for family history of thyroid disorders and hypertension.  
Comparison of adiposity: 
In our study mean BMI of cases were (24.87±4.3) and controls were 
(14.11±1.46) Mean Waist circumference in cases were (77.88±9.05) and 
controls were (52.63±4.91). 
In a study conducted by Huerta MG et al56 mean BMI in cases were 
(36.2 ± 2.1) and controls were (18.7± 0.6). In a study conducted by Bipin jose 
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et al 58 mean BMI in cases were (24.8 ± 5.0) and controls were (14.8 ± 2.2) 
Mean Waist circumference in cases were ( 85 ± 8.9) and controls were (58.3 ± 
6.8)  
The mean BMI is low in our cases compared to other studies, probably 
because of using IAP growth charts for BMI classification. 
Comparison of systolic and diastolic BP: 
In our study median (IQR) Systolic BP between the cases 100(90-110) 
and control 100(90-100) group were not statistically significant. p=0.064. 
Median (IQR) diastolic BP between the cases 70(60-70) and control 65(60-70) 
group were not statistically significant p=0.30. This is in contrast to study done 
by Bipin Jose et al58 and Ali M.Zaakouk  et al57. 
Bipin Jose et al58 conducted a study in 55 overweight and 53 normal 
weight individuals aged 4-14 years. The mean systolic BP in cases(118±16) 
and controls(102±10) showed statistical significance p<0.001. The mean 
diastolic BP in cases (78 ± 12) and controls (68 ± 7) also showed statistical 
significance p=<0.001. 
Ali M. Zaakouk et al57 study included 50 obese cases and 50 age and sex 
matched controls aged 2-16 years. Mean Systolic BP percentiles in cases 
(58.4±11.6) and controls (45.0±9.8) showed statistical significance p <0.001. 
Mean Diastolic BP percentiles in cases (62.2±9.9) and controls ( 57.4±12.3) 
also showed statistical significance p= 0.034. 
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Systolic and diastolic BP between cases and controls were not 
statistically significant in our study. This may be because in other studies age 
group range was higher upto 16 years in comparison to our study in which 
upper limit of age was 12 years 
Comparison of lipid profile: 
Mean serum triglycerides, cholesterol, HDL in cases (124.68±55.16, 
157.02±32.38, 39.54±8.09) and controls (90.80±23.60, 126.46±25.06, 
45.07±4.31) showed statistical significance p=<0.001. This finding is 
consistent with the study done by Ali M. Zaakouk et al57 in which the mean 
serum triglycerides, cholesterol, HDL in cases(107.1±17.0, 190.2±25.6, 51.3 
±7.5) and controls( 94.4± 22.3, 130.0± 30.8, 59.4± 11.4) showed statistical 
significance. 
This finding is consistent with the changes that occur in obesity and 
insulin resistance. Hall mark change that occur in obesity is increased flux of 
free fatty acids from the periphery to the liver that stimulates hepatic TG 
.Lipolysis is further impaired in obesity by reduced mRNA expression levels of 
Lipoprotein lipase (LPL) in adipose tissue and reduced LPL activity in skeletal 
muscle63. Hypertriglyceridemia further induces an increased exchange of 
cholesterol esters (CE) and TG between VLDL and HDL and low density 
lipoproteins (LDL) by cholesterylester-transfer-protein (CETP). This leads to 
decreased HDL-C concentrations and a reduction in TG content in LDL. In 
addition, hepatic lipase (HL) removes TG and phospholipids from LDL for the 
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final formation of TG-depleted small dense LDL which is an abnormal 
atherogenic particle. 
Comparison of electrolytes: 
Mean serum potassium, calcium in cases (4.19±0.22,9.13±0.36) and 
controls (4.23±023, 9.22±0.30) did not show a statistical significance 
p=(0.406,0.193).This is similar to study done by Huerta MG et al 56 in which 
mean serum potassium, calcium in cases (4.03±0.04,9.44±0.08) and 
controls(3.95±0.06,9.4±0.04) did not show a statistical difference. 
Even though there is no statistical significance in our study, in obesity 
low vitamin D levels can lead to hypocalcemia64 and this low serum calcium 
can lead to proliferation of adipocytes and further causes weight gain. 
Comparison of Liver enzymes: 
 Mean SGOT in cases (24.69±6.73) and controls (22.39±5.76) did not 
show statistical significance p=0.054 
 Median (IQR) SGPT in cases 20(17-26) and controls 18(14-22) did not 
show any statistical significance. P=0.051  
Though none of the studies quoted in literature review analysed the 
association of liver enzymes in obesity our finding of liver enzymes not 
showing statistical significance between cases and controls is supported by a 
Indian study done by Ajay Kumar Das65 in which the authors showed that there 
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is no significant relation between ALT, AST & GGT in normal, overweight 
and obese individuals. 
Comparison of fasting glucose: 
Mean serum fasting glucose(mg/dl) in cases (82.52±11.79) and 
controls(78.54±10.44) did not show any statistical significance=0.06 similar to 
study conducted by Huerta MG et al56 in which mean serum fasting 
glucose(mg/dl) in cases (92.88 ± 0.9) and controls (92.88 ± 1.8) p= 0.984 did 
not show statistical significance. 
Comparison of fasting insulin: 
Median (IQR) serum fasting insulin (μIU/mL) in cases 19.64(13.97-
27.89) and controls 7.50(5.21-10.39) showed a statistical significance 
p=<0.001 consistent with finding of the study done by Huerta MG et al56 in 
which median (IQR) of fasting insulin (/μIU/ml) in cases 26.91 (7.22–38.68)  
and controls 8.27 (3.72–15.87) showed a statistical significance p=0.001. Bipin 
Jose et al58 in his study showed that median (IQR) Serum insulin (μIU/mL) in 
cases 6.5 (4.1-11.9) and controls 3.2 (2.2-5.6) showed a statistical significance 
p= <0.001 
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Comparison of serum magnesium: 
 Mean serum magnesium (mg/dl) in cases (2.04±0.23) and controls 
(2.29±0.15) in our study showed statistical significance p=<0.001. This finding 
is similar to study done by  Huerta MG et al56 in which serum 
magnesium(mg/dl) in cases (1.82 ± 0.03) and controls( 1.94 ± 0.02) showed a 
statistical significance=0.009. In a study done by Bipin Jose et al 58  mean 
serum Mg (mg/dL) in cases  (2.12 ± 0.33) and controls( 2.56 ± 0.24) p= <0.001 
showed a statistical significance. Ali M. Zaakouk57 in his study showed that 
mean serum magnesium in cases (1.5 ±0.5) and controls( 2.4± 0.3) p= <0.001 
showed a statistical significance. Syed Awais ul Hassan et al62 in his study 
showed that mean serum magnesium in obese group (2.08 ± 0.211) and normal 
weight group (2.55 ± 0.155 ) showed a statistical significance. p=<0.001.  
 This can be explained by several studies which showed that in obesity,  
chronic inflammation and stress  leads to  low magnesium and low magnesium 
in obesity leads to inflammation and obesity related complications.  
Comparison of insulin resistance: 
In our study median (IQR) of insulin resistance index (HOMA-IR, 
QUICKI, FGIR) in cases (4.00(2.50-5.92), 0.31(0.3-0.33), 4.12(2.95-5.73)) and 
controls (1.35(1.00-2.00), 0.36(0.34-0.38), 9.80(7.55-15.21)) showed statistical 
significance p=<0.001. 
This observation is similar to study done by Huerta MG et al56 in which 
median(IQR) of HOMA-IR and QUICKI in obese( 5.70 (1.62–9.94), 0.30 
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(0.28–0.36)) and controls   (1.86 (0.77–3.54),0.35 (0.32–0.40) ) showed 
statistical significance. 
Mechanism of insulin resistance is explained by the mechanism that low 
serum magnesium in obesity hinders the action of insulin at its receptor level 
causing insulin resistance. 
Correlation between serum magnesium and insulin resistance: 
In our study there was an inverse correlation between serum magnesium 
with BMI, fasting insulin, HOMA-IR and positive correlation with QUICKI 
and FGIR consistent with the findings of Huerta MG et al56. 
Intragroup comparison: 
Intragroup comparison between obese(43 children) and overweight(13 
children) subjects  showed statistical significance for BMI (p=<0.001), Waist 
circumference(p=0.002) ,Fasting insulin(p=<0.001) , magnesium(p=<0.001) 
,HOMA-IR(p=0.003), QUICKI(p=0.004), FGIR(p=0.001). 
This statistical significance shows that serum magnesium and insulin 
resistance is mainly influenced by adiposity (BMI, waist circumference). As 
there is a significant difference in BMI and waist circumference between obese 
and overweight subjects, statistical difference in magnesium and indexes of 
insulin sensitivity between overweight and obese individuals is self-
explanatory. 
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CONCLUSION 
Serum magnesium in obese or overweight individuals is significantly 
low when compared to normal weight individuals. 
Waist circumference and Lipid profile (cholesterol, triglycerides, HDL) 
between obese and overweight also showed significant statistical difference. 
Low serum magnesium has significant negative correlation with BMI, 
fasting insulin, HOMA-IR and positive correlation with QUICKI, FGIR. 
Intragroup comparison between obese and overweight individuals in the 
levels of magnesium and indexes of insulin sensitivity (HOMA-IR, QUICKI, 
FGIR) was statistically significant which explains that degree of obesity 
(BMI,WC) determines magnesium and indexes of insulin sensitivity. 
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LIMITATIONS 
Dietary intake of magnesium in children was not taken into account  
Magnesium being an intracellular cation, the most sensitive index is 
measurement of intracellular magnesium which was not done 
The method used for measuring serum magnesium in our study was 
photometric end point assay in contrast to calorimetric or atomic absorption 
spectrometric method which is a better method of measuring serum 
magnesium. 
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RECOMMENDATIONS 
As the study proves that there is a significant correlation between serum 
magnesium levels with degree of adiposity and indexes of insulin sensitivity 
further research is needed whether magnesium supplementation by either 
increasing the dietary content or by extra supplementation can reverse or retard 
the progression of insulin resistance. 
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                    d) Thyroid  - Yes/No    If Yes, parent / sibling / grand parents 
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ANTHROPOMETRY 
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      3)>27 adult equivalent. 
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13. Waist circumference  a) in cm 
CLINICAL EXAMINATION 
14. Blood pressure  - a) Systolic -  
     b) Cat - 1) normal 2) prehypertension 3) hypertension stage1 
                  4) Hypertension stage 2. 
    c) Diastolic –  
     d) Cat - 1) normal 2) prehypertension 3) hypertension stage1 
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INVESTIGATIONS 
      15. Serum triglyceride    a) value –  
      16. Total cholesterol        a)value – 
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      23. SGPT                        a) value –  
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      26.Fasting glucose            a) value 
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Place of study: Endocrine OP, Institute Of Child Health And Hospital for  
      Children, Egmore, Chennai-8. 
Name of Investigator: Dr. S.CHIDAMBARAM 
Name of Participant:    Age:   Sex:  
Hospital No:      
Study title  
Relationship Between Serum Magnesium Levels And Insulin Resistance In 
Obese Children 
We request your child to participate in the study. 
Aim of the study- 
  This study aims at determining whether obese children have low serum 
magnesium concentration compared to normal lean individuals and whether 
low serum magnesium is correlated with insulin resistance. 
 Methods- 
  In order to find out the answers to the above questions, we will be 
checking your child’s height, weight and blood pressure. Further, we intend to 
draw 5 ml of venous blood from your child in fasting state along with blood 
drawn for other tests prescribed by your doctor and send it for analysis to fat 
level, insulin and magnesium in blood. This will take approximately ten 
minutes. 
Can I refuse to participate in the study? 
 Participation in the study is purely voluntary. You may refuse to 
participate or withdraw from the study at any time. In both cases the treatment 
  
and care your child receives from this hospital will not be affected in any 
manner. 
Benefits and harms of participating in the study- 
Your child will not benefit directly by participating in this study. But by way of 
participating in this study, your child is contributing to updation of science 
which may benefit her/him and all other patients with this disease in future. 
Drawing 5 ml blood from your child may be perceived as harm, but medically 
this will not compromise her/his health 
Confidentiality- 
 The data collected from the study will be used for the purpose of study 
only. The results of the study will be published. Personal information of the 
children participating in the study will be kept confidential. There will not be 
any disclosure about your child’s information without your permission. 
Subject rights- 
  If you wish further information regarding your child’s rights as a 
research participant, you may contact the principal investigator in the mobile 
number or address mentioned below. 
Principal Investigator –        Dr. S.CHIDAMBARAM 
Mobile number       -   9944369785 
Contact Address       -    Institute of Child Health and Hospital   
     for Children, Halls road, Egmore, Chennai. 
 
Place:  
Date:       Signature of Parent 
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Name of the investigator: Dr.S.CHIDAMBARAM     
Name of the Participant:  Age:   Sex: 
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1. I have read and understood the patient information sheet provided to me 
regarding the participation of my child in the study.  
2. I have been explained about the nature of the study and had my questions 
answered to my satisfaction.  
3. I have been explained about my rights and responsibilities by the 
investigator. 
4. I will allow my child to cooperate with the investigator and undergo clinical 
tests subjected during the study whole heartedly. 
5. I have been advised about the risks associated with my child’s participation 
in this study.* 
6. I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my child’s future treatment in 
this hospital. * 
7. I hereby give permission to the investigators to release the information 
obtained from my child as result of participation in this study to medical 
journals/conference proceedings. 
8. I understand that my child’s identity will be kept confidential if my child’s 
data are publicly presented/published.  
  
9. I have decided my child can participate in the research study. I am aware that 
if I have any question during this study, I should contact the investigator.  
10. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be 
given a copy of this consent document. 
 
Name and signature / thumb impression of the parent/guardian  
Name _________________________ Signature_________________ 
Date________________  
 
Name and Signature of the investigator  
Name _________________________ Signature________________ 
Date________________  
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Date________________ 
 
Name and Signature of impartial witness 2:  
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Date________________ 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAP  BMI  CHART  FOR  BOYS 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAP  BMI  CHART  FOR  GIRLS 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
